Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Does Simulations Plus (SLP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Simulations Plus (SLP) is a Great Momentum Stock to Buy

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus continues its 25th anniversary celebration with a $25,000 donation to St. Jude Children's Research Hospital.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus launches its Concierge Program to facilitate value-added strategic partnerships with customers to accelerate drug development.

Simulations Plus Realizes Early Success with its Concierge Program

SLP reported its Q3 earnings which beat expectations. The company is benefiting from increasing market adoption of its best-in-class drug development modeling tools.

Simulations Plus: Bullish Into Long-Term Earnings Runway

Simulations Plus' (SLP) Q3 results benefit from strength in the Software and Services' business.

Simulations Plus (SLP) Q3 Earnings & Revenues Top Estimates

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2022 Results Conference Call July 6, 2022 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - CEO Will Frederick - CFO Conference Call Participants Matt Hewitt - Craig-Hallum François Brisebois - Oppenheimer Dane Leone - Raymond James Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q3 2022 Results - Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of 17.65% and 5.94%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Q3 Earnings and Revenues Surpass Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports 3QFY22 total revenue growth of 17%; YTD total revenue up 15%, to $42.2 million. Quarterly dividend was declared by the Board.

Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results

Kornit Digital

With the US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Simulations Plus, Inc. (NASDAQ: SLP) to report quarterly earnings at $0.17 per share on revenue of $14.33 million after the closing bell.

Kornit Digital, Simulations Plus And 3 Stocks To Watch Heading Into Wednesday

Simulations Plus' (SLP) fiscal third-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus and ADMET predictor.

What to Expect Ahead of Simulations Plus (SLP) Q3 Earnings?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus 2nd Annual Pharmacometrics Spring School introduced MonolixSuite and PKanalix platforms to more than 900 attendees from 50 countries.

Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its Cognigen division worked with a major pharmaceutical company to accelerate the development of a COVID-19 therapy.

Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 3rd quarter fiscal year 2022 financial results on Wed., July 6, 2022, with a webcast at 5pm ET.

Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced important results published in the journal Toxicological Sciences predicting the safety of new CGRP molecules for migraine.

DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4) of its flagship machine learning modeling platform, ADMET Predictor®. Key enhancements include: New 3D conformer generation functionality to easily predict properties using advanced 3D molecular and atomic descriptors New mouse species models added to the HTPK Simul

Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the FDA renewed annual licenses to DILIsym, the DILIsym division's QST software for predicting drug-induced liver injury.

U.S. FDA Renews Annual DILIsym Software Licenses for 2022

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus successfully establishes the suitability of model-integrated evidence for BE studies of LAI drug products in FDA-funded project.

Simulations Plus Successfully Delivers FDA-Funded Project

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus entered a funded collaboration to advance innovative IVIVE methods for dissolution and precipitation modeling in its DDDPlus software

Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software

LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, chief executive officer of Simulations Plus, will be presenting at the Berenberg Discover AI Seminar in Boston, on April 26, 2022.

Simulations Plus to Present at the Berenberg Discover AI Seminar

Simulations Plus (SLP) Q2 results benefit from strength in the Software business. However, a decline in Services revenues acted as a headwind.

Simulations Plus (SLP) Q2 Earnings Top Estimates, Revenues Up

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q2 2022 Results - Earnings Call Transcript

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports total revenue of $14.8 million, up 13%, for the 2nd quarter of FY22 with software revenue growth of 25%, to $9.8 million.

Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will partner with the University of Pittsburgh to develop and validate its novel BIOLOGXsym QST software with funding from the NIH.

Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its 2022 MIDD+ Scientific Conference on Feb. 16-17, 2022, with speakers from the US FDA, ANVISA, Health Canada, & MHRA-UK.

Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 2nd quarter fiscal year 2022 financial results on Wed., April 6, 2022, with a webcast at 5pm ET.

News for Simulations Plus Stock (SLP)